160 related articles for article (PubMed ID: 16006442)
1. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key.
Montalescot G; Collet JP
Eur Heart J; 2005 Dec; 26(24):2616-22. PubMed ID: 16006442
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
5. The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.
Coyle JD; Gardner SF; White CM
Ann Pharmacother; 2004 Oct; 38(10):1731-8. PubMed ID: 15353571
[TBL] [Abstract][Full Text] [Related]
6. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
7. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
Karalliedde J; Viberti G
J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
Cantarovich F; Rangoonwala B
Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
10. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?
Ryan MJ; Tuttle KR
Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):443-9. PubMed ID: 18695383
[TBL] [Abstract][Full Text] [Related]
11. Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?
Laverman GD; de Zeeuw D; Navis G
J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):205-13. PubMed ID: 12584664
[TBL] [Abstract][Full Text] [Related]
12. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome: treatment of hypertensive patients.
Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
Bakris GL; Weir MR
Postgrad Med; 2008 Apr; 120(1):33-42. PubMed ID: 18467807
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
Tocci G; Sciarretta S; Facciolo C; Volpe M
Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
[TBL] [Abstract][Full Text] [Related]
16. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
17. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
18. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
Nickenig G; Ostergren J; Struijker-Boudier H
J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
[TBL] [Abstract][Full Text] [Related]
19. [Evidence-based usefulness of Ca antagonists and ACEIs and ARBs for the primary and secondary prevention of major cardiovascular and renal events in patients with hypertension].
Fujino T; Hasebe N; Kikuchi K
Clin Calcium; 2005 Oct; 15(10):1695-708. PubMed ID: 16199917
[TBL] [Abstract][Full Text] [Related]
20. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Makkar KM; Sanoski CA; Spinler SA
Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
